Roanna Ruiz

Q: What is Roanna Ruiz's success rate?

Roanna Ruiz currently has a success rate of 80.66332916145181.

Q: What is the average return of Roanna Ruiz's calls?

Their stock ratings have generated an average return of 51.17270981652198.

Leerink Partners | Healthcare

Roanna Ruiz is an analyst from Leerink Partners specializing in the Healthcare sector. Ranked #274 out of 4773 analysts, they have issued 7 stock ratings with a success rate of 80.66% and an average return of 51.17%.

With 7 ratings to date, Roanna Ruiz is beginning to establish credibility in the Healthcare sector. They have achieved a success rate of 80.66% and an average return of 51.17%, highlighting promising potential as their track record develops further.

#274

Out of 4773

Total Ratings

+80.66%

Success Rate

+51.17%

Average Return

Recent Ratings Analysis

XERS

Buy

Sep 10, 2026

Target

$16.00

Current

$7.45

Performance

-2.87%

Roanna Ruiz rated XERS as Outperform on Sep 10, 2026, setting a price target of 16. Shares have remained stable near 7.45, leaving the 16 target still in play.

KARD

Buy

Jul 13, 2026

Target

$37.00

Current

$18.52

Performance

-21.29%

On Jul 13, 2026, KARD was given a Outperform rating by Roanna Ruiz, with a target price of 37. Despite the Buy call, shares fell from 18.52 to 18.52, challenging the optimistic stance.

SPRY

Buy

Jun 25, 2026

Target

$24.00

Current

$4.76

Performance

-40.65%

SPRY received a Outperform rating from Roanna Ruiz on Jun 25, 2026, aiming for 24. The rating hasn’t played out as hoped, with the stock trading 40.65% below expectations.

VIR

Buy

Jun 03, 2026

Target

$21.00

Current

$10.62

Performance

21.09%

On Jun 03, 2026, Roanna Ruiz published a Outperform outlook on VIR, with a target of 21. Shares gained 21.09%, underscoring the accuracy of the bullish outlook toward 21.

CRMD

Buy

Apr 28, 2026

Target

$14.00

Current

$7.83

Performance

3.37%

Roanna Ruiz on Apr 28, 2026 assigned CRMD a Outperform rating, with a price target of 14. The recommendation remains pending validation as shares consolidate around 7.825.

CYTK

Buy

Feb 26, 2026

Target

$84.00

Current

$73.77

Performance

17.79%

On Feb 26, 2026, Roanna Ruiz reaffirmed CYTK with a Outperform rating, targeting 84. The recommendation was supported by strong follow-through as the stock rose from 73.77 to 73.77.

IBIO

Buy

Oct 17, 2025

Target

$2.00

Current

$1.21

Performance

41.76%

IBIO was rated Outperform by Roanna Ruiz on Oct 17, 2025, with a price objective of 2. A bullish response from the market helped close the gap of 0.79 to the target.

LXRX

Hold

Mar 04, 2025

Target

$1.00

Current

$2.00

Performance

515.76%

On Mar 04, 2025, Roanna Ruiz initiated coverage on LXRX with a Market Perform rating and target of 1. The Hold stance underestimated the stock’s strength as it gained 515.76%.

AQST

Buy

Sep 30, 2024

Target

$12.00

Current

$4.78

Performance

-4.02%

Roanna Ruiz issued a Outperform recommendation for AQST on Sep 30, 2024, price target set at 12. The target of 12 remains in play, though confirmation will depend on future moves.

Frequency Asked Questions

Who is Roanna Ruiz?

Roanna Ruiz is an analyst from Leerink Partners specializing in the Healthcare sector.

What is Roanna Ruiz's success rate?

Roanna Ruiz currently has a success rate of +80.66%.

How many ratings has Roanna Ruiz issued?

Roanna Ruiz has issued 7 stock ratings so far.

What is the average return of Roanna Ruiz's calls?

Their stock ratings have generated an average return of +51.17%.

What is Roanna Ruiz's ranking?

Roanna Ruiz is ranked #274 out of 4773 analysts.

What types of ratings does Roanna Ruiz give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow Roanna Ruiz?

You can follow Roanna Ruiz by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by Roanna Ruiz?

Their latest rating was a Buy on XERS issued on 2026-09-10.